Literature DB >> 29979988

Mapping Active Gene-Regulatory Regions in Human Repopulating Long-Term HSCs.

Peer Wünsche1, Elias S P Eckert1, Tim Holland-Letz2, Anna Paruzynski3, Agnes Hotz-Wagenblatt4, Raffaele Fronza5, Tim Rath5, Irene Gil-Farina5, Manfred Schmidt6, Christof von Kalle5, Christoph Klein7, Claudia R Ball8, Friederike Herbst9, Hanno Glimm10.   

Abstract

Genes that regulate hematopoietic stem cell (HSC) self-renewal, proliferation, and differentiation are tightly controlled by regulatory regions. However, mapping such regions relies on surface markers and immunophenotypic definition of HSCs. Here, we use γ-retroviral integration sites (γRV ISs) from a gene therapy trial for 10 patients with Wiskott-Aldrich syndrome to mark active enhancers and promoters in functionally defined long-term repopulating HSCs. Integration site clusters showed the highest ATAC-seq signals at HSC-specific peaks and strongly correlated with hematopoietic risk variants. Tagged genes were significantly enriched for HSC gene sets. We were able to map over 3,000 HSC regulatory regions in late-contributing HSCs, and we used these data to identify miR-10a and miR-335 as two miRNAs regulating early hematopoiesis. In this study, we show that viral insertion sites can be used as molecular tags to assess chromatin conformation on functionally defined cell populations, thereby providing a genome-wide resource for regulatory regions in human repopulating long-term HSCs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HSC; enhancer; hematopoietic stem cell; human; miRNA-10a; miRNA-335; non-coding regulatory regions; viral insertion sites

Mesh:

Substances:

Year:  2018        PMID: 29979988     DOI: 10.1016/j.stem.2018.06.003

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  7 in total

Review 1.  In vivo dynamics of human hematopoietic stem cells: novel concepts and future directions.

Authors:  Serena Scala; Alessandro Aiuti
Journal:  Blood Adv       Date:  2019-06-25

2.  CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration.

Authors:  Christopher L Nobles; Scott Sherrill-Mix; John K Everett; Shantan Reddy; Joseph A Fraietta; David L Porter; Noelle Frey; Saar I Gill; Stephan A Grupp; Shannon L Maude; Donald L Siegel; Bruce L Levine; Carl H June; Simon F Lacey; J Joseph Melenhorst; Frederic D Bushman
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

Review 3.  Detect accessible chromatin using ATAC-sequencing, from principle to applications.

Authors:  Yuanyuan Sun; Nan Miao; Tao Sun
Journal:  Hereditas       Date:  2019-08-15       Impact factor: 3.271

4.  Retroviral gene therapy in Germany with a view on previous experience and future perspectives.

Authors:  Michael A Morgan; Melanie Galla; Manuel Grez; Boris Fehse; Axel Schambach
Journal:  Gene Ther       Date:  2021-03-22       Impact factor: 5.250

Review 5.  Micro-RNAs: A safety net to protect hematopoietic stem cell self-renewal.

Authors:  Laura Crisafulli; Francesca Ficara
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-09-16       Impact factor: 9.349

6.  Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels.

Authors:  Wenliang Wang; Maria Fasolino; Benjamin Cattau; Naomi Goldman; Weimin Kong; Megan A Frederick; Sam J McCright; Karun Kiani; Joseph A Fraietta; Golnaz Vahedi
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-24       Impact factor: 11.205

7.  The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision.

Authors:  Friederike Herbst; Tonio J L Lang; Elias S P Eckert; Peer Wünsche; Alexander A Wurm; Tim Kindinger; Karin Laaber; Shayda Hemmati; Agnes Hotz-Wagenblatt; Oksana Zavidij; Anna Paruzynski; Junyan Lu; Christof von Kalle; Thorsten Zenz; Christoph Klein; Manfred Schmidt; Claudia R Ball; Hanno Glimm
Journal:  Leukemia       Date:  2021-05-21       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.